PDS Biotech Clinical Update and Financial Results by Mark Eisenberg 27.03.2024 Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
Vaccinex Expands Access to ActivMAb Antigen Virus Technology by Lilu Anderson 21.02.2024 ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...